Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells

被引:0
作者
Chen, Shuning [1 ,2 ]
Kong, Weimin [1 ]
Shen, Xiaochang [1 ,2 ]
Deng, Boer [1 ,2 ]
Haag, Jennifer [2 ]
Sinha, Nikita [2 ]
John, Catherine [2 ]
Sun, Wenchuan [2 ]
Zhou, Chunxiao [2 ,3 ]
Bae-Jump, Victoria L. [2 ,3 ]
机构
[1] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing Maternal & Child Hlth Care Hosp, Dept Gynecol, Beijing 100026, Peoples R China
[2] Univ N Carolina, Dept Obstet & Gynecol, Div Gynecol Oncol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
Uterine serous carcinoma; Sulindac; Cell proliferation; Invasion; COX-2; CANCER-RELATED INFLAMMATION; COLON-CANCER; CYCLOOXYGENASE-2; OVEREXPRESSION; UP-REGULATION; APOPTOSIS; CELECOXIB; PATHWAY; ARREST; ACTIVATION; INHIBITOR;
D O I
10.1007/s00432-024-05926-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeUterine serous carcinoma (USC) is a highly aggressive and frequently recurring subtype of endometrial cancer with limited treatment options for advanced or recurrent stages. Sulindac, a classic non-steroidal anti-inflammatory drug, has demonstrated anti-tumor activity in several pre-clinical tumor models. This study aims to evaluate the effect of sulindac on cell proliferation and invasion in USC cells.MethodsHuman USC cell lines ARK-1 and SPEC2 were treated with different concentrations of sulindac. Cell proliferation was assessed using MTT and colony formation assays. ELISA assays measured cellular stress, cleaved caspase 3 activity, antioxidant ability, and adhesion. Cell cycle arrest was evaluated by Cellometer. The invasive capability was detected by wound healing assay. Western blotting was used to analyze the changes in protein expression induced by sulindac.ResultsExposure to sulindac decreased cellular viability in a dose-dependent manner in ARK-1 and SPEC2 cells. Sulindac effectively inhibited cell cycle progression, increased cellular stress, caused apoptosis, and reduced cell adhesion and invasion in USC cells. Additionally, sulindac decreased the expression of COX-2 and blocked phosphorylation of NF-kappa B induced by TNF-alpha.ConclusionSulindac is a potential therapeutic agent for USC that deserves further exploration in pre-clinical studies and potentially future clinical trials.
引用
收藏
页数:11
相关论文
共 48 条
  • [1] Sulindac induces differentiation of glioblastoma stem cells making them more sensitive to oxidative stress
    Allani, S. K.
    Weissbach, H.
    Lopez-Toledano, M. A.
    [J]. NEOPLASMA, 2018, 65 (03) : 376 - 388
  • [2] Prophylactic aspirin intake and breast cancer risk; A systematic review and meta-analysis of observational cohort studies
    Bakierzynska, Martyna
    Cullinane, Ms Carolyn
    Redmond, Henry Paul
    Corrigan, Mark
    [J]. EJSO, 2023, 49 (10):
  • [3] Uterine serous carcinoma
    Bogani, Giorgio
    Ray-Coquard, Isabelle
    Concin, Nicole
    Ngoi, Natalie Y. L.
    Morice, Philippe
    Enomoto, Takayuki
    Takehara, Kazuhiro
    Denys, Hannelore
    Nout, Remi A.
    Lorusso, Domenica
    Vaughan, Michelle M.
    Bini, Marta
    Takano, Masashi
    Provencher, Diane
    Indini, Alice
    Sagae, Satoru
    Wimberger, Pauline
    Poka, Robert
    Segev, Yakir
    Kim, Se Ik
    dos Reis, Francisco J. Candido
    Lopez, Salvatore
    Mariani, Andrea
    Leitao, Mario M., Jr.
    Raspagliesi, Francesco
    Panici, Pieluigi Benedetti
    Di Donato, Violante
    Muzii, Ludovico
    Colombo, Nicoletta
    Scambia, Giovanni
    Pignata, Sandro
    Monk, Bradley J.
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 (01) : 226 - 234
  • [4] Boolbol SK, 1996, CANCER RES, V56, P2556
  • [5] Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
    Borneman, Rebecca M.
    Gavin, Elaine
    Musiyenko, Alla
    Richter, Wito
    Lee, Kevin J.
    Crossman, David K.
    Andrews, Joel F.
    Wilhite, Annelise M.
    McClellan, Steven
    Aragon, Ileana
    Ward, Antonio B.
    Chen, Xi
    Keeton, Adam B.
    Berry, Kristy
    Piazza, Gary A.
    Scalici, Jennifer M.
    da Silva, Luciana Madeira
    [J]. JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)
  • [6] Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis
    Burke, Carol A.
    Dekker, Evelien
    Lynch, Patrick
    Samadder, N. Jewel
    Balaguer, Francesc
    Huneburg, Robert
    Burn, John
    Castells, Antoni
    Gallinger, Steven
    Lim, Ramona
    Stoffel, Elena M.
    Gupta, Samir
    Henderson, Alex
    Kallenberg, Frank G.
    Kanth, Priyanka
    Roos, Victorine H.
    Ginsberg, Gregory G.
    Sinicrope, Frank A.
    Strassburg, Christian P.
    Van Cutsem, Eric
    Church, James
    Lalloo, Fiona
    Willingham, Field F.
    Wise, Paul E.
    Grady, William M.
    Ford, Molly
    Weiss, Jennifer M.
    Gryfe, Robert
    Rustgi, Anil K.
    Syngal, Sapna
    Cohen, Alfred
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (11) : 1028 - 1039
  • [7] Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1
    Cha, Byong-Ki
    Kim, Young-Suk
    Hwang, Ki-Eun
    Cho, Kyung-Hwa
    Oh, Seon-Hee
    Kim, Byoung-Ryun
    Jun, Hong-Young
    Yoon, Kwon-Ha
    Jeong, Eun-Taik
    Kim, Hak-Ryul
    [J]. ONCOTARGET, 2016, 7 (35) : 57213 - 57227
  • [8] Endometrial cancer
    Crosbie, Emma J.
    Kitson, Sarah J.
    McAlpine, Jessica N.
    Mukhopadhyay, Asima
    Powell, Melanie E.
    Singh, Naveena
    [J]. LANCET, 2022, 399 (10333) : 1412 - 1428
  • [9] Cancer-related inflammation and treatment effectiveness
    Diakos, Connie I.
    Charles, Kellie A.
    McMillan, Donald C.
    Clarke, Stephen J.
    [J]. LANCET ONCOLOGY, 2014, 15 (11) : E493 - E503
  • [10] Cyclooxygenase-2 in cancer: A review
    Goradel, Nasser Hashemi
    Najafi, Masoud
    Salehi, Eniseh
    Farhood, Bagher
    Mortezaee, Keywan
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5683 - 5699